– IRELAND – Venn Life Sciences Holdings Plc (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Gracielle Anna Maria Beijerbacht-Schutjens to the Board as an Executive Director with immediate effect.
Gracielle, aged 48, has over 18 years of clinical development experience. After completing her studies in health education and biology, she progressed through the clinical research industry from a clinical research associate to starting her own contract research organisation in 2001, which was subsequently acquired by Venn Life Sciences B.V. (a subsidiary of the Company) in 2010. Having worked with a broad range of pharmaceutical, biotechnology and medical device companies, Gracielle has managed clinical trials across multiple sites with extensive investigator relationships throughout the Benelux region and is a member of a number of professional research associations.
Commenting on the appointment, Venn CEO, Tony Richardson, said: “We are very pleased to welcome Gracielle to the Board as an Executive Director. Gracielle’s experience of multi-site clinical trials and relationships will be a benefit to Venn as we continue to execute our strategy of becoming a leading mid-sized CRO in Europe.”
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation – Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division – Innovenn – focused primarily on breakthrough development opportunities in Skin Science.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.